10.5 DEVELOPMENTAL FUNDS Developmental Funds are critical to the future progress of the OSUCCC. During the prior funding period, the OSUCCC benefited from $1,858,197 in CCSG developmental funds. For the $1,308,482 of CCSG dollars used for faculty recruitment, the return to date in total direct costs for CCSG-approved peer-reviewed extramural funding is $ 28,576,879 (22:1 return on investment), and in total funding was $72,421,123 (55:1 return on investment, Table 1). In addition, we used CCSG funds for establishment of two shared resources, the Microarray Shared Resource and the Real Time PCR Shared Resource. A brief summary of the progress with these two facilities is described below, because their operation as fully established shared resources is described elsewhere in this application. In the 1999 CCSG competing renewal, """"""""Developmental Funds"""""""" received a merit descriptor of """"""""excellent"""""""". It was noted that there was no letter of assurance from the University attesting to the statement that developmental funds would be matched on a 10:1 basis, nor was there a clear outline of just how or in what form the University funds would be provided in supplementing the developmental funds. There were additional concerns that the junior to mid-level positions to be recruited during the last two years of the grant period were inadequate in description. Finally, there were concerns that the recruitment of a research mammographer might not be possible without a more research-oriented climate in radiology. In the present application, we provide evidence that the University is now providing the new OSUCCC Director with over $9 M/year in funds, an increase of over $8.5 M/year since our last competitive renewal. These dollars are to be used entirely to continue to develop the cancer program at OSU and as such, are matching to any CCSG dollars provided for this purpose. Written assurance of this $9 M/year commitment from both the OSU President and the Senior Vice President for Health Sciences is provided in section 6.7 of Essential Characteristics. In the present application we have tried to provide a more complete description of all 11 faculty we intend to recruit with CCSG developmental funds. In response to the concerns of first establishing a research environment in imaging prior recruiting a research mammographer, we first invested in recruiting a world-class imaging researcher who has initiated the development of a palpable research program in radiology, now making it more suitable to pursue additional imaging investigators. We are requesting support for continued faculty recruitment and continued shared resource development. We propose to focus our recruitment on 11 new faculty: two in the area of cancer prevention and control, three in basic or translational aspects on solid tumor oncology (breast, gastrointestinal, and prostate), one faculty member for each of biostatistics, pathology and human imaging research and three basic researchers in human cancer genetics. We request CCSG funds to develop three new shared resources (SR): a small animal imaging SR, a pharmacoanalytical SR and a cancer biomedical informatics SR. Both our Internal and External Scientific Advisors believe that strategically directed recruitment and SR development are the two best ways to continue to use new developmental funds, given the success with these funds to date and the resultant growth of the OSUCCC over the past 4 years. In Section 10.5.2, we describe our request for developmental funds for the next funding period. Section 10.5.3 describes the resources available to the OSUCCC to supplement the requested `$1 M annually in developmental funds. Our request represents less than 25% of our total annual direct CCSG request.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-34
Application #
7743474
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2010-11-30
Budget Start
2008-12-01
Budget End
2010-11-30
Support Year
34
Fiscal Year
2009
Total Cost
$960,595
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Norquist, Barbara M; Brady, Mark F; Harrell, Maria I et al. (2018) Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clin Cancer Res 24:777-783
Zhang, Bin; Nguyen, Le Xuan Truong; Li, Ling et al. (2018) Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nat Med 24:450-462
Tasselli, Giorgia; Filippucci, Sara; Borsella, Elisabetta et al. (2018) Yeast lipids from cardoon stalks, stranded driftwood and olive tree pruning residues as possible extra sources of oils for producing biofuels and biochemicals. Biotechnol Biofuels 11:147
Moliva, J I; Hossfeld, A P; Canan, C H et al. (2018) Exposure to human alveolar lining fluid enhances Mycobacterium bovis BCG vaccine efficacy against Mycobacterium tuberculosis infection in a CD8+ T-cell-dependent manner. Mucosal Immunol 11:968-978
Suarez-Kelly, Lorena P; Akagi, Keiko; Reeser, Julie W et al. (2018) Metaplastic breast cancer in a patient with neurofibromatosis type 1 and somatic loss of heterozygosity. Cold Spring Harb Mol Case Stud 4:
Malpeli, Giorgio; Barbi, Stefano; Greco, Corinna et al. (2018) MicroRNA signatures and Foxp3+ cell count correlate with relapse occurrence in follicular lymphoma. Oncotarget 9:19961-19979
Talbert, Erin E; Lewis, Heather L; Farren, Matthew R et al. (2018) Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients. J Cachexia Sarcopenia Muscle 9:358-368
Wang, Jin-Ting; Xie, Wen-Quan; Liu, Fa-Quan et al. (2018) NADH protect against radiation enteritis by enhancing autophagy and inhibiting inflammation through PI3K/AKT pathway. Am J Transl Res 10:1713-1721
Karpurapu, Manjula; Lee, Yong Gyu; Qian, Ziqing et al. (2018) Inhibition of nuclear factor of activated T cells (NFAT) c3 activation attenuates acute lung injury and pulmonary edema in murine models of sepsis. Oncotarget 9:10606-10620
Behnfeldt, Julia Harris; Acharya, Samir; Tangeman, Larissa et al. (2018) A tri-serine cluster within the topoisomerase II?-interaction domain of the BLM helicase is required for regulating chromosome breakage in human cells. Hum Mol Genet 27:1241-1251

Showing the most recent 10 out of 2602 publications